Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases [3] - The company's lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), targets CD19 and has the potential to change treatment paradigms for multiple B-cell-driven autoimmune diseases [3] - Kyverna is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [3] Upcoming Events - Warner Biddle, the CEO of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, at 9:45 a.m. PT [1] - A live audio webcast of the presentation will be available on the Investors section of the Kyverna website, with a replay accessible for 30 days post-conference [2] Research and Development - The company is also conducting trials for other conditions, including multiple sclerosis and rheumatoid arthritis, to inform future indications [3] - Kyverna's next-generation pipeline includes CAR T-cell therapies that incorporate novel innovations aimed at improving patient access and experience [3]